Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 17, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 18, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-031015
Filed / recorded
Mar 18, 2026, 9:46 PM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ORAMED PHARMACEUTICALS INC.
Issuer CIK
1176309
Ticker
ORMP
Reporting person
Miriam Kidron
Relationship
Director, Officer
Officer title
Chief Scientific Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Mar 17, 2026
Transaction code
A
Shares / units
119,558
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
1,568,222
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in 8 quarterly installments beginning April 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share, of the Issuer.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.